Latest news with #Karuna
Hans India
3 days ago
- Health
- Hans India
Mask up Telangana
Hyderabad: In the wake of a spike in the Covid cases and 26 deaths so far in the country, health experts in the city have cautioned common people to wear masks for at least four weeks. Dr Madap Karuna, consultant at EMRI Green Health Services, who deals with preventive healthcare, stressed on masking up. She said that there were many unreported Covid cases in Telangana as a few of the fellow doctors were mentioning. Karuna said that people need to wear masks for at least four weeks in crowded places, hospitals and diagnostic centres. 'If you have fever, cough, cold, please wear a mask to protect your family, colleagues and near and dear,' said Dr Karuna. According to the dashboard of the Union Health Ministry, there were close to 4,000 positive cases in the country. The total positivity rate was 0.2 per 1 lakh population and the total fatality rate was at 0.8 per 100 cases. The Kerala state alone accounts for 42.3 per cent of total active cases. Maharashtra follows with 15.6 per cent, Delhi (294 cases) and Gujarat (223) together making up 19 per cent of the total burden. The South Indian states (Kerala, Karnataka, Tamil Nadu, Andhra Pradesh, Telangana) together account for over 58 per cent of all cases. Maharashtra reported the highest number of deaths (7), accounting for nearly 32 per cent of the total deaths followed by Kerala with 5 deaths (23 per cent), Delhi and Karnataka each reported 2 deaths, jointly contributing 18 per cent. Dr Karuna further said that the government alone can't control, and the public should oblige with precautions. 'These illnesses can be controlled if we become alert when we see fumes, not when we see fire. Most important antibiotic abuse for these viral infections can be stopped by knowing the case pattern in our surroundings," she explained. Concurring with her views, Dr Kiran Madhala from the Telangana State chapter of the Indian Medical Association (IMA), said that following precautions was always a better option. He said that after May 2025, a total of 72 Covid-19 genome sequences were recorded in the country. Among these, the JF.7.9 variant accounted for the highest proportion, comprising 25 sequences or approximately 34.72 per cent. The XFG variant followed closely with 24 sequences (33.33 per cent), and the XFJ variant was found in 15 sequences (20.83 per cent). The JN.1 variant appeared in two sequences (2.78 per cent), while the remaining six sequences (8.33 per cent) were classified as others.
Pink Villa
26-05-2025
- Entertainment
- Pink Villa
Bhairavam release date, plot, full star cast: All about Bellamkonda Sai Srinivas and Manchu Manoj's Telugu film
Bhairavam is an upcoming Telugu action drama that is just days away from its theatrical release. Starring Bellamkonda Sai Srinivas and Manchu Manoj in the lead roles, the film has been drawing significant attention from netizens. If you're planning to catch it in theaters, read on for all the key details. Bhairavam release date and star cast Bhairavam will hit the big screens this week on May 30, 2025. The film features Bellamkonda Sai Sreenivas, Nara Rohith, and Manoj Manchu as the main leads. The star cast also includes Jayasudha, Divya Pillai, Sampath Raj, Sandeep Raj, Ajay, Aditi Shankar, Aanandi, Raja Ravindra, Sarath Lohitashwa, and Vennela Kishore. The movie is directed and written by Vijay Kanakamedala, produced by KK Radhamohan, and presented by Dr. Jayantilal Gada under PEN Studios. Cinematography is handled by Hari K Vedantam. Bhairavam trailer and plot Bhairavam is the Telugu remake of the Tamil action drama Garudan, which starred Soori. The story of the original film revolved around Sokkan, a loyal aide raised by Karuna after saving his life as a child. Sokkan becomes the trusted companion of Karuna and his close friend Aadhi. All three grow up together, bonded over shared past and deep emotional ties. As adults, Karuna and Aadhi become powerful figures in their village, managing temple affairs. However, their relationship begins to crumble due to manipulation, greed, and betrayal from those around them. Sokkan finds himself torn between loyalty and justice as dark secrets unravel. When Karuna turns against Aadhi and commits a shocking crime, Sokkan is forced to make a life-altering decision. Bhairavam OTT release According to a Times Now report, the Zee Group has secured both the digital and satellite rights for Bhairavam in a deal worth Rs 32 crore. The agreement includes OTT and TV broadcasting rights. After completing its theatrical run, the Telugu action drama is expected to stream on the ZEE5 platform. Additionally, the movie will have its television premiere on its channel, Zee Telugu. With this acquisition, Bhairavam is set for a wide post-theatrical reach across digital and satellite platforms.
Business Upturn
22-05-2025
- Business
- Business Upturn
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
– Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. ('Serina') (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization. Most recently, he served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical strategy for KarXT (xanomeline–trospium), the first new mechanism of action for schizophrenia approved in over 30 years. KarXT's successful development and launch were key to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024. 'Steve brings a rare depth of clinical and strategic expertise in neuroscience drug development, and we're pleased to welcome him to the Board,' said Steve Ledger, Chief Executive Officer of Serina Therapeutics. 'At Karuna, he helped shape the clinical path for KarXT, a first-in-class therapy that ultimately drove one of the largest CNS acquisitions in recent years. His experience designing thoughtful, data-driven trials and his understanding of patient and commercial needs are highly aligned with Serina's focus on long-acting treatments for movement disorders and other CNS conditions. We look forward to his contributions as we advance our pipeline toward the clinic.' Dr. Brannan previously held senior leadership roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, where he directed clinical development programs in depression, Alzheimer's disease, schizophrenia, and treatment-resistant epilepsy. At Takeda, he led turnaround efforts that rescued and advanced multiple late-stage CNS programs. He is a founding member of the CNS Summit Leadership Council and has served on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM), reflecting his continued influence on the field's evolving standards and methodologies. Dr. Brannan received his A.B. from Harvard University and his M.D. from the University of Texas Southwestern Medical School. He completed residency and fellowship training in psychiatry and neuroimaging, and has served in academic, clinical, and industry leadership roles throughout his career. Serina also announced the departure of Remy Gross from its Board of Directors. Mr. Ledger stated, 'Remy has been a trusted advisor to the team at Serina for many years. We thank Remy for his contributions to Serina's growth from private to public company and his continuing support of the team in a new consulting role. ' About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit For inquiries, please contact:Stefan Riley [email protected] (256) 327-9630
Yahoo
22-05-2025
- Business
- Yahoo
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ('Serina') (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization. Most recently, he served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical strategy for KarXT (xanomeline–trospium), the first new mechanism of action for schizophrenia approved in over 30 years. KarXT's successful development and launch were key to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024. 'Steve brings a rare depth of clinical and strategic expertise in neuroscience drug development, and we're pleased to welcome him to the Board,' said Steve Ledger, Chief Executive Officer of Serina Therapeutics. 'At Karuna, he helped shape the clinical path for KarXT, a first-in-class therapy that ultimately drove one of the largest CNS acquisitions in recent years. His experience designing thoughtful, data-driven trials and his understanding of patient and commercial needs are highly aligned with Serina's focus on long-acting treatments for movement disorders and other CNS conditions. We look forward to his contributions as we advance our pipeline toward the clinic.' Dr. Brannan previously held senior leadership roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, where he directed clinical development programs in depression, Alzheimer's disease, schizophrenia, and treatment-resistant epilepsy. At Takeda, he led turnaround efforts that rescued and advanced multiple late-stage CNS programs. He is a founding member of the CNS Summit Leadership Council and has served on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM), reflecting his continued influence on the field's evolving standards and methodologies. Dr. Brannan received his A.B. from Harvard University and his M.D. from the University of Texas Southwestern Medical School. He completed residency and fellowship training in psychiatry and neuroimaging, and has served in academic, clinical, and industry leadership roles throughout his career. Serina also announced the departure of Remy Gross from its Board of Directors. Mr. Ledger stated, 'Remy has been a trusted advisor to the team at Serina for many years. We thank Remy for his contributions to Serina's growth from private to public company and his continuing support of the team in a new consulting role. " About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit For inquiries, please contact:Stefan Riley sriley@ (256) 327-9630Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ('Serina') (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization. Most recently, he served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical strategy for KarXT (xanomeline–trospium), the first new mechanism of action for schizophrenia approved in over 30 years. KarXT's successful development and launch were key to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024. 'Steve brings a rare depth of clinical and strategic expertise in neuroscience drug development, and we're pleased to welcome him to the Board,' said Steve Ledger, Chief Executive Officer of Serina Therapeutics. 'At Karuna, he helped shape the clinical path for KarXT, a first-in-class therapy that ultimately drove one of the largest CNS acquisitions in recent years. His experience designing thoughtful, data-driven trials and his understanding of patient and commercial needs are highly aligned with Serina's focus on long-acting treatments for movement disorders and other CNS conditions. We look forward to his contributions as we advance our pipeline toward the clinic.' Dr. Brannan previously held senior leadership roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, where he directed clinical development programs in depression, Alzheimer's disease, schizophrenia, and treatment-resistant epilepsy. At Takeda, he led turnaround efforts that rescued and advanced multiple late-stage CNS programs. He is a founding member of the CNS Summit Leadership Council and has served on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM), reflecting his continued influence on the field's evolving standards and methodologies. Dr. Brannan received his A.B. from Harvard University and his M.D. from the University of Texas Southwestern Medical School. He completed residency and fellowship training in psychiatry and neuroimaging, and has served in academic, clinical, and industry leadership roles throughout his career. Serina also announced the departure of Remy Gross from its Board of Directors. Mr. Ledger stated, 'Remy has been a trusted advisor to the team at Serina for many years. We thank Remy for his contributions to Serina's growth from private to public company and his continuing support of the team in a new consulting role. " About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit For inquiries, please contact:Stefan Riley sriley@ (256) 327-9630Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
